Skip to content Skip to sidebar Skip to footer
Subscribe Now
Viewpoints_Michael Scheffler
VIEWPOINTS

Michael Scheffler, Vice President, Head of Life Science PCR at QIAGEN Shares Insights on the Addition of New Biopharma Products to its Digital PCR Portfolio

Shots:Michael spoke about the addition of new biopharma products through QIAcuity series of digital PCR (dPCR) instruments to its digital PCR portfolioHe also talked about how QIAGEN’s dPCR assays are quicker than systems as it was launched in four different master mixes allowing experiments leading to precise resultsThe interview gives an understanding of…
October 12, 20220Comments

Read more

ThoughtSpot_Saurabh Chaubey
THOUGHTSPOT

Competitive Intelligence: A Substantial Advantage for the Pharmaceutical Sector

“The supreme art of war is to subdue the enemy without fighting” – Sun Zhu, Competitive Intelligence benefits your organization gather and analyzing information related to your competitor’s business models. This deep analysis helps your organization reduce the strategic risks and increase revenue opportunities by attaining deep insights into how the market has changed and…
October 11, 20220Comments

Read more

Viewpoints_Alex Zimmerman_Alexander Lin
VIEWPOINTS

Alex Zimmerman and Alexander Lin Share Insights on the FDA Breakthrough Device Designation Received for Non-Invasive Virtual Biopsy Technology

Shots:Alex Zimmerman talked about virtual biopsy technology using standard MRI scanners. The technology will allow doctors to understand brain imaging via chemical indicators more extensivelyAlexander Lin spoke about the data on which the BDD was granted by the FDA and the usage of Magnetic Resonance Spectroscopy (MRS) by this softwareBrainSpec is a…
October 10, 20220Comments

Read more

Insights+ Key Biosimilars Events of September 2022
INSIGHTS+

Insights+ Key Biosimilars Events of September 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of September, Fresenius Kabi’s Stimufend (biosimilar, pegfilgrastim) received the…
October 6, 20220Comments

Read more

Viewpoints_Erika Ross
VIEWPOINTS

Erika Ross, Director of Clinical & Applied Research at Abbott Shares Insights on FDA Breakthrough Device Designation to Explore its DBS System to Treat Treatment-Resistant Depression

Shots: Erika spoke about the FDA Breakthrough Device Designation received by Abbott to investigate its deep brain stimulation (DBS) system to treat treatment-resistant depression (TRD)Erika also talked about how NeuroSphere Virtual Clinic is compatible with the  deep brain stimulation (DBS) system The interview gives an understanding of Abbott’s vision to bring life-changing technologies in…
October 5, 20220Comments

Read more

Viewpoints_Yoshio Okubo
VIEWPOINTS

Yoshio Okubo, Senior Director, Head of Pandemic Global Product Team for Takeda Shares Insights on the Approval of its Covid-19 Vaccine

Shots:Yoshio spoke about the approval of the Nuvaxovid COVID-19 Vaccine for Primary and Booster Immunization in Japan. Nuvaxovid Intramuscular Injection is the first recombinant protein-based COVID-19 vaccine approved for use in JapanYoshio also talked about Takeda’s collaboration with Novavax for the development, manufacturing, and commercialization of Nuvaxovid in JapanFurther, the interview highlighted…
October 4, 20220Comments

Read more

Exclusive_Nagesh Mahanthappa_2022
EXCLUSIVE

Nagesh Mahanthappa, Interim CEO of Scholar Rock Shares Insights on Treatment Options for Spinal Muscular Atrophy

Shots:Nagesh talked about how Spinal Muscular Atrophy (SMA) is affecting people all over the world and how Scholar Rock’s treatment options are improving the lives of those living with this diseaseNagesh also spoke about Scholar Rock’s lead product in SMA, apitegromab, highlighting its trial designs (TOPAZ & SAPPHIRE trials), outcomes, and real-world data…
October 3, 20220Comments

Read more

Disease of the Month: Duchenne Muscular Dystrophy (DMD)
INSIGHTS+

Disease of the Month: Duchenne Muscular Dystrophy (DMD)

INTRODUCTIONDuchenne Muscular Dystrophy (DMD) is a rare and the most frequent genetic neuromuscular disorder affecting all races and ethnicities (affecting approximately 1 in 3,500 population). It is characterized by progressive muscle weakness and some specific abnormalities like changes in muscle fiber size, scar tissue formation, muscle fiber necrosis, and inflammation evidenced from muscle biopsy…
September 29, 20220Comments

Read more